The present invention relates to humanized monoclonal antibodies that have high binding affinity for the tumor-associated glycoprotein (TAG)-72 with minimal immunogenicity. This anti-TAG-72 antibody binds to the same epitope as the CC49 murine variant developed at the National Cancer Institute. The variants of CC49 described in this patent application have been shown to have a decreased immune response, with comparable binding affinity, than the parent murine antibodies.
These variants have potential benefits for use in the detection and/or treatment of a range of human carcinomas.
由于技术保密工作限制,技术信息无法完全展现,请通过邮箱或短信联系我们,获取更多技术资料。
oncofetal antigen expressed
murine monoclonal antibody
present invention relates
humanized monoclonal antibodies
anti-tag-72 antibody binds